secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001213900-23-064560
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Therapeutics Q2 net loss narrows to $51.1M; cash $409.4M, runway into mid-2026
--------------------------------------------------------------------------------

- Net loss $51.1M ($0.27/shr) vs $159.1M loss in Q2 2022; revenue $20.5M vs $21.6M.
- Cash and marketable securities $409.4M, down from $505.0M at Dec 31, 2022; expects to fund ops into mid-2026.
- R&D expense $29.7M (down 30% YoY) due to bempegaldesleukin wind-down; restructuring charges $16.6M.
- Plans Phase 2b study of rezpegaldesleukin in atopic dermatitis; initial data in H1 2025; IND submission in 2024.
- Corrected rezpegaldesleukin efficacy data previously miscalculated by Eli Lilly; evaluating NKTR-255 partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390023064560/0001213900-23-064560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390023064560/ea183032-8k_nektarther.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-064560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer